Hyloris Pharmaceuticals Statistics

Total Valuation

Hyloris Pharmaceuticals has a market cap or net worth of GBP 125.97 million. The enterprise value is 104.17 million.

Market Cap	125.97M
Enterprise Value	104.17M

Important Dates

The next estimated earnings date is Thursday, March 20, 2025.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.44%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	12.09M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	4.82
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-9.28
EV / Sales	17.95
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.96

Financial Position

The company has a current ratio of 3.71, with a Debt / Equity ratio of 0.05.

Current Ratio	3.71
Quick Ratio	3.66
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.15
Interest Coverage	-141.88

Financial Efficiency

Return on equity (ROE) is -31.76% and return on invested capital (ROIC) is -19.79%.

Return on Equity (ROE)	-31.76%
Return on Assets (ROA)	-16.75%
Return on Invested Capital (ROIC)	-19.79%
Return on Capital Employed (ROCE)	-37.59%
Revenue Per Employee	143,530
Profits Per Employee	-273,846
Employee Count	41
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -56.58% in the last 52 weeks. The beta is 0.56, so Hyloris Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.56
52-Week Price Change	-56.58%
50-Day Moving Average	5.82
200-Day Moving Average	n/a
Relative Strength Index (RSI)	46.12
Average Volume (20 Days)	436

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hyloris Pharmaceuticals had revenue of GBP 5.88 million and -11.23 million in losses. Loss per share was -0.40.

Revenue	5.88M
Gross Profit	5.75M
Operating Income	-11.67M
Pretax Income	-11.23M
Net Income	-11.23M
EBITDA	-11.47M
EBIT	-11.67M
Loss Per Share	-0.40

Full Income Statement

Balance Sheet

The company has 23.70 million in cash and 1.60 million in debt, giving a net cash position of 22.10 million.

Cash & Cash Equivalents	23.70M
Total Debt	1.60M
Net Cash	22.10M
Net Cash Per Share	n/a
Equity (Book Value)	29.39M
Book Value Per Share	1.01
Working Capital	20.29M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.19 million and capital expenditures -271,302, giving a free cash flow of -10.46 million.

Operating Cash Flow	-10.19M
Capital Expenditures	-271,302
Free Cash Flow	-10.46M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 97.77%, with operating and profit margins of -198.27% and -190.79%.

Gross Margin	97.77%
Operating Margin	-198.27%
Pretax Margin	-190.79%
Profit Margin	-190.79%
EBITDA Margin	-194.86%
EBIT Margin	-198.27%
FCF Margin	n/a

Dividends & Yields

Hyloris Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.44%
Shareholder Yield	-1.44%
Earnings Yield	-8.91%
FCF Yield	-8.30%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Hyloris Pharmaceuticals has an Altman Z-Score of 15.92.

Altman Z-Score	15.92
Piotroski F-Score	n/a